Novartis shelled out $200 million as part of a multiyear alliance with Aduro Biotech for preclinical cyclic dinucleotides. And Merck Serono paid $115 million to access Intrexon’s chimeric antigen T-cell (CART) technology. Aduro’s cyclic dinucleotides activate the stimulator of interferon genes, or STING, pathway, triggering a broad immune response directed at tumor cells.
by Lisa M. Jarvis |
April 03, 2015